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Abstract
Background: The	prevalence	of	dementia	is	increasing	rapidly.	People	with	dementia	
may	be	prescribed	complex	medication	regimens,	which	may	be	challenging	for	them	
and	any	carers	involved	to	safely	manage.
Objective: To	describe	and	understand	the	key	challenges,	in	relation	to	medication	
issues,	experienced	by	people	with	dementia	and	their	informal	carers	dwelling	in	the	
community	and	the	potential	role	of	community	pharmacists.
Design: Qualitative	semi-	structured	interviews.
Participants: People	with	dementia,	informal	carers	and	health	and	social	care	profes-
sionals	(HSCPs).
Results: Thirty-	one	participants	 (eleven	 informal	 carers,	 four	 people	with	dementia	
and	sixteen	HSCPs)	were	interviewed.	Three	key	themes	were	identified:	the	key	chal-
lenges,	 improving	medication	management	 and	 the	 role	of	 pharmacists.	 The	 caring	
role	 commonly	 included	 responsibility	 for	 medication	 management	 which	 created	
both	practical	problems	and	an	emotional	burden.	This	burden	was	worsened	by	any	
difficulty	in	obtaining	support	and	if	the	person	with	dementia	was	on	a	complex	regi-
men.	Participants	believed	 that	 the	process	could	be	 improved	by	coordinated	and	
on-	going	support	from	HSCPs,	which	should	focus	on	the	informal	carer.	Medication	
reviews,	particularly	when	conducted	in	the	home	environment,	could	be	helpful.
Conclusion: Medication	management	for	people	with	dementia	living	in	the	community	
is	a	complex	process,	and	informal	carers	have	a	key	role,	which	they	frequently	find	
challenging.	Community	pharmacists	could	have	an	enhanced	role	in	this	area,	but	would	
need	to	work	within	a	more	multidisciplinary	environment	outside	the	pharmacy.
K E Y W O R D S
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1  | INTRODUCTION
It	 is	 estimated	 that	 dementia	 has	 a	 global	 prevalence	 of	 47.5	mil-
lion	individuals.1	In	the	UK,	800	000	people	live	with	dementia	–	this	
figure	is	expected	to	double	by	2040	reflecting	global	predictions.1,2 
The	presence	of	dementia	potentially	increases	the	likelihood	of	the	
presence	for	risk	factors	for	adverse	drug	reactions	such	as	 lack	of	
pharmacy	 input,	 drug	 interactions,	 comorbidity	 and	 polypharmacy,	
2  |     MAIDMENT ET Al.
amongst	 others.3–6	 The	 cognitive	 impairment	 characteristic	 of	 de-
mentia	 may	 result	 in	 a	 lack	 of	 capacity	 to	 safely	 self-	administer	
medication.7,8	 Despite	 people	 with	 dementia	 being	 particularly	
susceptible	 to	 adverse	drug	events,	 they	 are	 commonly	prescribed	
complex	medication	 regimes	 and	 on	 average	 receive	 five	 different	
medicines.7,9
Medication	 management	 “is	 the	 entire	way	 that	 medicines	 are	
selected,	procured,	delivered,	prescribed,	administered	and	reviewed	
to	optimize	 the	 contribution	 that	medicines	make	 to	 producing	 in-
formed	 and	 desired	 outcomes	 of	 patient	 care”.10	 With	 increasing	
cognitive	 impairment,	 the	 core	 symptom	 of	 dementia,	 medication	
management	is	often	shifted	from	the	personal	responsibility	of	the	
person	with	dementia	to	the	control	of	formal	(paid)	or	informal	(fam-
ily)	 carers	 particularly	 with	 complex	 regimens.11–15	 Informal	 carers	
often	have	a	key	role	in	ensuring	safe	and	effective	medication	use	as	
they	may	conduct	up	to	10	medication	management	activities	every	
day,	including	awareness	of	and	managing	side-	effects,	and	decisions	
to	 administer	 medication.16,17	 Previous	 research	 has	 identified	 the	
role	of	informal	carers	as	advocates	and	their	potential	contribution	
to	 patient	 safety.18	 Unlike	 health	 professionals,	 family	 and	 friends	
who	are	informal	carers	may	not	receive	any	training	or	have	access	
to	evidence-	based	 information	to	appropriately	support	medication	
management.17,19	In	fact,	 informal	carers	may	not	feel	equipped	for	
such	an	augmented	role	which	they	can	find	burdensome	and	stress-
ful	and	this	in	turn	may	affect	the	informal	carer’s	and	the	person	with	
dementia’s	quality	of	life.20–24
Without	the	support	and	collaboration	of	health	professionals	in-
volved,	informal	carers	may	struggle	to	adequately	support	medication	
management	especially	of	complex	regimes.8	However,	some	health-	
care	 professionals	 lack	 time	 and	 awareness	 of	 the	 administration	
practicalities	and	the	realities	of	informal	carers	and	people	with	de-
mentia.25,26	Furthermore,	the	information	about	medication	regimens,	
provided	by	health-	care	professionals,	can	be	complex	and	sometimes	
is	not	directly	communicated	to	the	informal	carer	due	to	the	restric-
tion	of	confidential	information.17,19,26
The	role	of	community	pharmacists	is	changing	from	being	focused	
on	 the	 supply	 of	medicines	 to	 providing	 clinical	 services.27,28 These 
services	 are	 focused	on	helping	 patients	 obtain	 the	optimal	 benefit	
from	prescribed	medication	by	advising	other	clinicians	and	working	
directly	with	patients	and	others.29–32	The	change	in	role	is	supported	
by	national	and	international	policy.29,33	The	available	literature	argues	
that	community	pharmacy	services	available	for	people	with	dementia	
are	poorly	developed	and	 the	need	 for	 further	 research	on	ways	 to	
optimize	medication	management	 in	 people	with	 dementia	 living	 in	
the	community	has	been	identified.25,34
It	is	important	then	to	explore	the	perspectives	of	the	key	stake-
holders,	including	informal	carers	and	people	with	dementia,	to	under-
stand	how	community	pharmacists	can	support	people	with	dementia	
living	in	the	community	with	safe	medication	management.	The	objec-
tives	of	the	study	were	to	describe	and	understand	the	key	challenges,	
in	relation	to	medication	issues,	experienced	by	people	with	dementia	
and	their	informal	carers	dwelling	in	the	community,	and	the	potential	
role	of	community	pharmacists.
2  | METHODS
2.1 | Design
An	 exploratory	 qualitative	 study	 design	 that	 followed	Consolidated	
Criteria	 for	Reporting	Qualitative	studies	 (COREQ)	guidelines35 was 
employed	(see	appendix	for	further	details).	A	focus	group	conducted	
at	 the	 Alzheimer’s	 Society	 and	 involving	 informal	 carers	 had	 previ-
ously	identified	the	need	for	research	in	this	area.26
2.2 | Participants and recruitment
Participants	were	 recruited	 from	the	Alzheimer’s	Society,	Dementia	
UK,	local	General	Practice	(GP)	surgeries,	professional	networks	and	
local	dementia	support	groups	(including	a	support	group	for	people	
with	dementia	from	the	Black	and	Minority	Ethnic	[BME]	community	
in	Yorkshire).	The	 institutions	were	contacted	by	LA	and	IM	via	tel-
ephone	and	email	and	were	enquired	about	their	willingness	to	col-
laborate	 in	 advertising	 the	 study.	 Recruitment	 was	 also	 conducted	
through	snowball	effect	as	contacts	were	requested	to	suggest	other	
people	with	dementia,	informal	carers	and	HSCPs	who	might	be	will-
ing	to	take	part	in	this	study.
2.3 | Data collection
Semi-	structured	face-	to-	face	interviews	were	conducted.	Two	inter-
view	guides	were	used:	one	for	people	with	dementia	and	their	infor-
mal	carers	and	one	for	HSCPs	(see	appendix	for	further	details).	This	
was	the	selected	type	of	interview	as	it	gives	participants	the	oppor-
tunity	to	expand	their	answers	freely	and	to	provide	in-	depth	reflec-
tions	about	their	lived	experiences.	Furthermore,	it	allowed	obtaining	
data	 that	 were	 suitable	 for	 conducting	 a	 Framework	 analysis.	 On	
three	occasions,	both	the	informal	carer	and	the	person	with	demen-
tia	were	together	in	the	room	during	the	interview.	This	allowed	the	
person	with	dementia	to	provide	further	insight	into	what	the	informal	
carer	was	saying.	Each	interview	lasted	between	30	and	60	minutes.	
Interpreters	 from	 the	 same	 community	were	 used	 for	 all	 the	 inter-
views	with	informal	carers	from	the	BME	community.
2.4 | Inclusion criteria
Informal	carers	were	eligible	if:
•	 They	 had	 provided	 or	 still	 provide	 some	 sort	 of	 assistance	with	
medication	management	to	a	person	who	has	been	diagnosed	with	
dementia	and	is	living	in	the	community;
•	 Did	not	 receive	 any	 sort	 of	 payment	 (excluding	 receipt	 of	 carers’	
allowance).
HSCPs	were	eligible	if:
•	 They	had	been	in	contact	with	or	had	been	providing	assistance	to	
people	with	dementia
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2.5 | Data analysis
A	qualitative	framework	analysis	was	undertaken	in	order	to	explore	
the	 experiences	 and	 perspectives	 of	 the	 participants.	 Framework	
analysis,	which	has	been	specifically	designed	for	applied	qualitative	
research	that	commences	deductively	from	specified	aims	and	objec-
tives,	was	used	to	organize	and	make	sense	of	the	data.36,37	NVIVO	
software	was	used	to	manage	the	data.
The	 transcripts	 were	 transcribed	 verbatim.	 TM	 and	 IM	 inde-
pendently	 reviewed	 the	 transcripts.	Disagreements	on	 the	 interpre-
tation	and	analysis	of	the	data	were	then	discussed	between	TM	and	
IM.	 Any	 disagreements	 or	 differences	 in	 interpretation	 of	 the	 data	
between	TM	and	IM	were	resolved,	as	necessary,	with	discussions	in-
volving	the	wider	team	(with	AH	the	final	arbiter)	until	consensus	was	
achieved.	A	systematic	cross-	comparison	analysis	was	undertaken	by	
TM,	and	reviewed	by	IM	to	identify	the	similarities	and	differences	be-
tween	the	different	participants	and	to	develop	a	set	of	themes	which	
represent	the	whole	corpus	of	data.	TM	and	 IM	then	discussed	and	
agreed	the	final	structure	of	the	matrix	for	the	analysis.
3  | RESULTS
Thirty-	one	participants,	eleven	informal	carers,	four	people	with	de-
mentia,	sixteen	HSCPs	(four	GPs,	five	nurses,	three	social	care	profes-
sionals	 [paid	 formal	 carers]	 and	 four	 community	 pharmacists),	were	
interviewed.	Three	main	themes	were	identified.	Key	challenges	expe-
rienced	by	informal	carers	and	people	with	dementia	(the	caring	role,	
the	challenges	of	the	condition),	 improving	medication	management	
in	 people	 with	 dementia	 (empowerment	 and	 communication	 from	
health	professionals)	and	the	role	of	pharmacists.
3.1 | Key challenges experienced by informal 
carers and people with dementia: the caring role, the 
challenges of the condition
Interviews	with	 informal	carers	and	people	with	dementia	provided	
information	on	the	challenges	that	they	experience	in	relation	to	med-
ication	management.	Nearly	half	of	the	carers	reported	that	they	had	
no	problem	in	terms	of	the	practicalities	of	managing	the	medication.	
Although	 it	 is	a	complex	process,	by	adopting	an	organized	routine,	
carers	reported	that	the	practical	aspects	of	managing	medication	did	
not	have	any	impact	on	their	lives:
So in your opinion, does managing your medication affect 
your daily life 
(question from research associate)?
Not really, no, not really. I’ve got it sussed out. 
(Informal carer; pp3).
No, not really, no. It’s all right if I do it in advance (discuss-
ing organising the medication), you see, I know what to do, 
so… It’s really three times a day I have to remember. But 
then it’s usually when we’re eating, so it’s part of the ritual 
with the food. 
(Informal carer; pp4).
Some	(but	not	all)	informal	carers	stated	that	compliance	packs	could	
help	them	organize	the	medication:
Before this sort of thing came out which I didn’t know 
about, they came in a small bottle and, obviously, you 
have to take certain ones at certain times. Well, I used 
to get into a right two and eight (Cockney rhyming slang 
for a state). And it…well, it just was a muddle. And then 
(community pharmacy chain), I used to go to (community 
pharmacy chain), and then they started putting them into 
packs like this. 
(Informal carer; pp2).
However,	 there	 is	 still	 frequently	 an	 emotional	 burden	 associated	
with	 medication	 management	 and	 carers	 expressed	 an	 obligation	 to	
being	responsible	for	managing	the	medication	of	the	person	they	are	
looking	 after;	 this	 included	 prioritizing	 the	 health	 of	 the	 person	 they	
cared	for	over	their	own	health:
Sometimes I feel fed up but what can I do? That is my 
duty…I forget my medicine but I never forget his 
(Informal carer; pp27).
On	further	exploration,	informal	carers	linked	this	burden	to	the	fact	
that	 the	medication	was	 not	 improving	 the	 behaviours	 and	 cognitive	
problems	characteristic	of	dementia:
I was frustrated with myself. Why? With the medicine and 
she was getting worse and worse…the way she was behav-
ing that I was worried about. 
(Informal carer – pp25).
Ensuring	adherence	to	medication	may	be	difficult.	Due	to	increasing	
cognitive	impairment,	the	person	with	dementia	may	not	understand	the	
need	for	medication.	Again,	the	difficulties	proliferate	as	the	complexity	
of	the	regimen	increases,	potentially	making	the	person	with	dementia	
very	dependent	on	the	carer:
I wouldn’t know which ones to take, there’s too many of 
them. 
(Person with dementia; pp1).
I have missed (doses of medication) occasionally. 
(Person with dementia; pp11.)
According	to	some	informal	carers,	their	caring	duty	was	shown	to	be	
particularly	challenging	when	medication	needed	to	be	taken	at	different	
times	of	the	day:
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So all these [health issues] require medication…It’s keeping 
them separate that is the real problem 
(Informal carer; pp14).
Moreover,	keeping	track	of	the	supply	of	medication	was	also	high-
lighted	as	being	a	potential	difficulty:
Make sure that you got enough tablets to last 
(Informal carer; pp3).
I think the main problem with the medication was having 
to go and get it and remembering, “Oh, there’s only that 
many left of that particular one, I’d better order some 
more.” And I seemed to be up and down there twice a 
week. 
(Informal carer; pp4)
The	impact	that	taking	care	of	the	medication	of	a	person	with	de-
mentia	has	on	the	carer	may	be	even	more	evident	when	they	are	forced	
to	 make	 decisions	 about	 administering	 medication	without	 sufficient	
support	from	HSCPs:
And now I discovered we’ve run out of brown (Warfarin) 
and they didn’t bother to give as a prescription for it and 
it was the weekend. And I was going to go to the doctor 
but what I did was I’ve got a pill cutter. (OK). I cut the 
blue into two, I hope that’s the correct dosage, I don’t 
know. 
(Informal carer; pp14).
Lack	of	access	to	doctors	was	seen	as	a	barrier	to	effective	medica-
tion	management.	Clinicians’	lack	of	time	to	address	carers’	or	patients’	
concerns	was	flagged	by	several	informal	carers:
This is what I feel I need to see Dr X, I really do. I feel 
that the tablets that she’s on, they are not doing any-
thing. I often wonder, sort of, to experiment and not 
give her any tablets at all for a week and see what the 
outcome would be. But then it might be dangerous. It 
could be you know, she could just fall off the planet. 
This is why I want to speak to him. But it’s like trying to 
see the Pope. 
(Informal carer; pp2).
Thus,	informal	carers	often	need	to	decide	whether	or	not	to	follow	
instructions,	or	change	the	regimen	without	seeking	advice:
[Doctor said] Every three days, but I don’t give it to her 
every three days because it’s a morphine patch, it’s for 
pain. She isn’t saying that she’s…any pain. Following the 
prescription she’d be taking 8 paracetamol a day which I 
think is far too much to be honest with you. 
(Informal carer – pp16).
3.2 | Improving medication management in people 
with dementia: empowerment and communication 
from health professionals
All	groups	(people	with	dementia,	informal	carers	and	HSCPs)	identi-
fied	that	people	with	dementia	and	their	informal	carers	needed	more	
support	 with	 medication	 management.	 Medication	 management	 is	
frequently	solely	dependent	on	informal	carers,	and	therefore,	target-
ing	them	is	the	best	way	to	improve	the	process:
I find organising things in the short term, I find it difficult 
(Person with dementia; pp1).
So that’s where the help needs to be improved, em-
powering carers…You can’t empower the patients be-
cause they’re already losing them (to the symptoms of 
dementia). 
(GP; pp5).
Yet,	 informal	 carers	may	 have	 their	 own	 health	 problems	 and	
therefore	 have	 to	 manage	 the	 medication	 of	 two	 people:	 them-
selves	 and	 the	person	 they	 care	 for.	The	majority	of	 the	 informal	
carers	agreed	that	having	to	manage	both	regimens	can	be	difficult	
as there is:
A lot to think about. Yes. That’s why I like to think about 
and with (the person with dementia cared for) not being 
on the ball, sort of business…I have to think about as 
well. 
(Informal carer - pp3).
HSCPs	need	 to	provide	 clear	 explanations	 so	 that	 informal	 carers	
fully	understand	the	treatments	 in	order	to	decrease	the	risk	of	medi-
cation	errors:
If they’ve sat there in a consultation and me or anyone 
else…”Oh, they’ve completely got that” and then a few 
months later…although the drug is no longer on…their 
medical records, at home they’ve still got boxes of tablets 
and they’re still taking them and they shouldn’t be 
(GP; pp15)
Therefore,	HSCPs	should	supply:
A little bit more…explanation…and then it’s easier to take 
that in and we’ll keep that in our memories’. 
(Informal carer; pp1)
Furthermore,	informal	carers	believed	that	medication	management	
could	be	improved	if	HSCPs:
Listen to the concerns of the relatives 
(Informal carer; pp14)
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It	was	identified	by	a	HSCP	that	written	communication	in	addition	
to	verbal	could	be	used	as	a	way	to	help	ensure	that	informal	carers	and	
people	with	dementia	understand	their	treatment:
Written instructions, pictures and making sure that their…
family understand what to do. 
(Nurse; pp9)
However,	this	topic	needs	to	be	addressed	carefully	as	the	infor-
mation	needs	to	be	tailored	to	person	with	dementia	and	their	infor-
mal	 carer.	 It	 is	 important	 to	 not	 only	 provide	 the	 right	 instructions	
for	the	right	 illness	but	make	sure	that	the	person	has	the	ability	to	
understand	the	message	(as	the	earlier	quote	from	the	GP	pp15	also	
highlighted):
It’s crazy. You need a magnifying glass as well as your 
glasses to read it, don’t you? 
(Informal carer; pp1).
HSCPs	identified	that	a	coordinated	response	involving	several	pro-
fessionals	was	needed	to	support	medication	management:
Well, if they’re having problems taking it at the right time 
then I would say social services because they’d need 
prompting to take it. If it was because they couldn’t open 
bottles or they were getting pills mixed up, because you, 
like, you might get several tablets that look the same. You 
know, so that would be the pharmacist because you need 
identification. If it was because, like with PRN medication, 
you would maybe need a nurse to help them identify when 
they needed certain drugs. 
(Nurse – pp12)
Some	informal	carers	agreed	with	this	idea	and	added	that	this	sup-
port	 needs	 to	 take	 into	 consideration	different	 cultural	 traditions	 and	
religions:
Whoever is looking after (the person with dementia) if 
they (clinicians) are not aware of these issues, cultural 
issues, religious issues and traditions…then it’s a big 
problem…you have to build the confidence according to 
their traditions or religion so it plays a major part in that 
situation if you’re not aware (of cultural and religious 
 aspects)…South Asian people (may) have little knowledge 
about English. 
(Informal carer; pp25)
In	 addition,	 medication	 reviews	 were	 viewed	 as	 having	 a	 poten-
tially	positive	impact,	but	clinicians	may	lack	the	time	to	conduct	them	
adequately:
In a 20 minute appointment and looking at their medica-
tion is just one part of that…most people will probably say, 
“No, no, its fine, I’m taking them”. But actually, you know, I 
don’t know how in depth we go, really. 
(Nurse; pp7).
Again,	it	is	important	that	HSCPs	coordinate	any	review	and	share	
relevant	 information	 between	 themselves	 to	 improve	 the	 support	
given	and	the	treatment.	Failing	to	do	this	may	lead	to	several	issues:
Although the information does come back to us through 
the GPs, it may not always be the type of information 
that we always want…that patient may not be as well 
 adherent…and not presenting it to the doctor. 
(Pharmacist; pp23)
According	 to	most	of	 the	HSCPs	 interviewed,	medication	 reviews	
have	 significant	 potential	 to	 improve	 medication	 management	 but	
should	be	conducted	in	the	patient’s	home	so	that	HSCPs	understand	
the	full	picture	of	the	whole	process:
That’s easier isn’t it when you are out there seeing them in 
their home. It’s very difficult when people come in because 
you have no idea really…like I say, things can sound very 
chaotic but actually when you are in there, you think, “Oh, 
no, it’s OK, it’s working”. It’s very difficult when you are not 
actually seeing it for yourself. 
(Nurse; pp7)
Lastly,	it	was	highlighted	that	medication	review	should	focus	on	
decreasing	the	complexity	of	the	regimen	and	include	any	formulation	
issues,	which	can	be	a	barrier	to	adherence.	The	objective	of	the	whole	
process	is	making	the	medication	regimen	easy	to	follow:
If you’ve got a choice of inhaler but have these twice a 
day…or there’s one that’s once a day you’d, hopefully, go 
for the one that’s once a day one if it carries the appro-
priate medication. So, it’s just simplifying everything…get 
them the best medication possible, make it simple and 
then they are going to use it. 
(Nurse; pp9)
3.3 | The role of pharmacists
HSCPs	identified	the	role	of	pharmacists	in	giving	advice	on	medication.	
However,	informal	carers	and	people	with	dementia	tended	to	focus	on	
practical	aspects	of	the	role,	such	as	home	delivery	of	medication,	and	
viewed	their	role	in	terms	of	the	supply	of	medication	without	mention-
ing	or	indeed	knowing	about	the	clinical	roles	pharmacists	can	provide:
Well, it’s got to be the doctors, hasn’t it, and nurses… 
they’re the ones, aren’t they (that provide support for med-
ication management)…rather than the pharmacists…they 
just provide it (medication), don’t they. 
(Informal carer; pp1)
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So how do you think pharmacists could improve support 
to people with dementia and their carers when it comes to 
managing the medication? 
(Question from research associate)
Yes, I mean they could give…they can sort the tablets out 
for them and put them in a pillbox. 
(Informal carer; pp3)
Non-	pharmacist	HSCPs	confirmed	that	people	may	not	be	aware	of	
the	benefits	of	getting	advice	from	community	pharmacists	on	medica-
tion,	which	is	not	the	best	use	of	the	pharmacists’	skills:
Well, I think we’re very lucky in this country in that we do 
have a community network of expert pharmacists who are 
under- utilised, whose expertise is under- utilised. 
(GP; pp8)
HSCPs	highlighted	the	need	for	pharmacists	to	play	a	more	active	
role	in	the	multidisciplinary	team.	One	way	of	achieving	this	would	be	
having	pharmacists	working	in	GP	surgeries:
The main thing is if the pharmacist is attached to the prac-
tice and to the patient that would be great…I mean, why 
haven’t they [doctors] got such good relationships with 
pharmacists… here’s the store of knowledge. 
(GP; pp8).
Additionally,	all	four	community	pharmacists	argued	that	having	ac-
cess	to	the	patient’s	medical	records	would	be	a	starting	point	to	improve	
the	 support	 they	provide	 to	 people	with	 dementia	 and	 their	 informal	
carers:
Well, I think the community pharmacists are left out of 
the clinical loop, the loop of communication between GPs, 
specialist nurses and the hospital…they don’t realise the 
potential for the community pharmacist to be a referral, 
you know, to co- ordinate…If we had access to medical 
records…we’d be better able to support them (i.e. the 
patient/carer). 
(Pharmacist; pp 21)
This	 idea	was	explored	even	further	by	some	participants,	and	a	
nurse	suggested	that	having	a	specialist	designated/named	pharma-
cist	with	 the	 knowledge	 to	 educate	 could	mean	 better	 support	 for	
medication	management	to	people	with	dementia	and	their	informal	
carers:
Somebody in pharmacies that oversees all dementia 
 patients…named contact for families that if they are con-
cerned they can contact…who was responsible for that 
patient’s medication. 
(Nurse; pp7)
A	further	suggestion	was	made	in	terms	of	having	community	phar-
macists	going	on	home	visits	 in	order	to	understand	how	people	with	
dementia	and	their	informal	carers	are	coping	with	their	medication	and	
help	to	develop	strategies	to	address	any	issues:
Pharmacist that could go and visit people at home. 
(GP; pp15)
People (who) are alone, or, like, the carer isn’t up to doing 
it, or feeling it’s too much 
(Informal carer; pp4)
Pharmacists	recognized	that	the	advice	and	role	they	can	provide	is	
limited	without	home	visits.	However,	 the	current	 funding	model	may	
not	routinely	support	home	medication	reviews:
We do not have a commissioned service where we can do 
medicines use reviews at the patient’s home. However, my 
colleagues in the neighbouring (area)…do have it…and it’s 
shown to be a valuable service. 
(Pharmacist; pp23)
4  | DISCUSSION
Medication	management	for	people	with	dementia	living	in	the	com-
munity	is	often	a	very	complex	task	and	supported	by	a	triad	of	the	
person	with	dementia,	 informal	 carers	 and	various	HSCPs.	 Informal	
carers	have	a	pivotal	role,	but	yet	frequently	find	managing	the	medi-
cation	 of	 someone	 with	 dementia	 challenging.	 Indeed,	 even	 carers	
who	stated	that	they	had	everything	under	control	identified	a	‘duty	
to	cope’	and	associated	emotional	burden.	This	echoes	 the	findings	
elsewhere	where	 informal	 carers	 identified	 that	 any	 failure	 to	 cope	
would	be	viewed	as	their	fault.26,38,39	This	challenge	increased	as	the	
complexity	of	the	regimen	increases	and	if	the	carers	lacked	adequate	
support,	 again	 echoing	 previous	 research.11,16,25,26	 Limited	 English	
proficiency	also	increased	the	difficulties.5
The	challenges	associated	with	medication	management	for	peo-
ple	with	dementia,	their	informal	carers	and	the	wider	society	can	have	
potentially	serious	consequences.	There	is	an	increased	risk	of	people	
with	dementia	experiencing	a	medication	error,	as	clearly	seen	in	the	
accounts	 from	 both	 HSCPs	 and	 carers,	 and	 previously	 identified.40 
Making	sure	that	their	loved	one	takes	the	right	medication	at	the	right	
time	places	a	significant	emotional	burden	on	the	informal	carer,	which	
is	not	always	acknowledged	by	the	HSCP.	Additionally,	if	informal	car-
ers	fail	to	cope,	this	has	wider	implications	for	society	because	further	
resources	 such	 as	 admission	 to	 residential	 care	 may	 be	 required.21 
Other	research	on	the	challenges	for	informal	carers	in	the	manage-
ment	of	Behavioural	and	Psychological	Symptoms	of	Dementia	(BPSD)	
also	found	a	‘sense	of	shame’	if	the	carers	failed	to	cope	and	that	the	 
burden	is	often	hidden	from	HSCPs.38,39
As	far	as	we	are	aware,	this	is	the	first	study	that	has	focused	on	
the	barriers	to	community	pharmacists	supporting	informal	carers	of	
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people	with	dementia.	Other	 studies	have	 found	barriers	 to	a	more	
clinical	role	for	community	pharmacists	in	the	management	of	BPSD28 
and	pain	in	people	with	dementia.41	Similar	to	our	research,	the	phar-
macists	in	these	studies	believed	that	a	lack	of	training	and	multidis-
ciplinary	working	and	lack	of	access	to	clinical	records	inhibited	their	
input.28,41	 Equally	 importantly,	 we	 found,	 like	 other	 research,	 that	 
informal	 carers	 tended	 to	 view	 the	 role	 of	 pharmacists	 in	 terms	 of	
medication	supply.5,26
Other	 studies	 have	 identified	 high	 levels	 of	 polypharmacy	 with	
potentially	inappropriate	prescribing	in	people	with	dementia	ranging	
from	22%4	 to	81.5%	of	participants.6	We	 found	 that	medication	 re-
view	focussing	on	simplifying	the	regimen	might	be	helpful,	particularly	
if	delivered	 in	the	home	environment.	However,	a	systematic	review	
found	that	pharmacist-	led	chronic	disease	management	increased	the	
complexity	of	the	medication	regimen.42	Ultimately,	it	is	essential	that	
HSCPs	adopt	a	person-	centred	approach	and	pay	attention	to	the	chal-
lenges	that	informal	carers	and	people	with	dementia	face.	This	should	
include	exploring	ways	to	reduce	any	burden	on	informal	carers	associ-
ated	with	managing	medication.
More	 generally,	 medicine	 optimization	 –	 defined	 as	 a	 ‘person-	
centred	approach	to	safe	and	effective	medicines	use,	to	ensure	peo-
ple	 obtain	 the	 best	 possible	 outcomes	 from	 their	 medicines’	 –	 has	
been	identified	a	key	priority	within	primary	care.43,44 Further research 
on	how	to	 improve	outcomes	from	medication	and	deliver	medicine	
optimization	is	needed.44	Deprescribing	which	is	considered	to	be	‘the	
process	 of	withdrawal	 of	 inappropriate	medication,	 supervised	 by	 a	
health-	care	professional	with	the	goal	of	managing	polypharmacy	and	
improving	outcomes’	may	represent	a	promising	approach	to	medicine	
optimization.45	However,	evidence	on	the	impact	of	deprescribing	in	
older	people	is	equivocal	and	further	evidence	from	controlled	studies	
is	required.46
4.1 | Implications for clinicians and policymakers
Clinicians	 and	policymakers	 need	 to	be	 aware	of	 the	 challenges	 in-
volved	and	 that	even	 informal	 carers	who	do	not	 report	difficulties	
may	be	experiencing	an	emotional	burden.	Evidence-	based	guidelines	
need	to	consider	this	burden,	which	is	worsened	as	the	complexity	of	
the	 regimen	 increases.	 There	 is	 a	 potential	 for	 community	 pharma-
cists	to	work	outside	the	‘four	walls’	of	the	community	pharmacy	in	
order	to	support	people	with	dementia	and	their	informal	carers	man-
age	their	medication.47	This	‘work	without	boundaries’	should	include	
medication	reviews	 in	the	patient’s	home,	needs	full	access	to	clini-
cal	 records	 and	 be	 coordinated	with	 other	medication	 optimization	
	activity.48	 Whilst	 home-	based	 medication	 reviews	 are	 occurring	 in	
some	areas,	this	research	found	inconsistencies	between	regions.	This	
need	to	review	medication	in	the	patient’s	own	home	would	equally	
apply	to	practice-	based	pharmacists.
4.2 | Strengths and weaknesses
The	study	has	a	number	of	potential	strengths.	Data	were	triangulated	
from	the	perspectives	of	different	HSCPs,	informal	carers	and	people	
with	 dementia.	 Participants	 were	 recruited	 from	 various	 locations	
and	data	saturation	was	achieved	for	the	complete	set	of	interviews,	
based	on	criteria	from	Fusch	et	al.49
Like	all	research,	there	are	limitations.	Findings	are	context-	bound	
to	 the	 participants	 and	 study	 setting,	 like	 all	 qualitative	 research.50 
Although	we	believe	that	the	testimonies	from	the	participants	were	
particularly	rich	 in	content,	as	data	were	obtained	from	face-	to-	face	
interviews,	we	cannot	avoid	the	possibility	that	participants	may	have	
given	socially	desirable	 responses.	Only	a	 limited	number	of	partici-
pants	from	the	BME	community	were	interviewed.
4.3 | Future research
Further	research	would	benefit	from	exploring	the	perspectives	of	a	
more	diverse	sample	including	people	from	the	BME	community;	this	
study	only	 included	people	 from	 the	South	Asian	BME	community,	
and	people	with	dementia	living	alone.	A	future	project	could	also	fol-
low	a	cohort	of	people	with	dementia	and	their	informal	carers	longi-
tudinally	to	gain	further	insights	on	how	the	challenges	change	as	the	
dementia	progresses.
Ultimately,	this	research	can	inform	the	development	of	an	inter-
vention.	Set	within	the	Medical	Research	Council	 (MRC)	framework,	
a	feasibility	study	of	a	pharmacist-	led	home	medication	review	in	col-
laboration	with	other	HCSPs	should	be	conducted.	The	 intervention	
should	be	tailored	to	the	specific	needs	of	the	person	with	dementia	
and	their	informal	carer.38,39
5  | CONCLUSIONS
Medication	management	in	people	with	dementia	living	in	the	com-
munity	is	frequently	a	very	complex	process.	As	dementia	develops,	
medication	management	becomes	the	responsibility	of	informal	car-
ers,	who	frequently	have	little	or	no	medical	experience	or	knowledge.	
Informal	carers	frequently	find	this	role	challenging,	particularly	when	
the	person	with	dementia	lacks	an	understanding	of	the	need	for	med-
ication.	This	challenge	was	compounded	by,	at	times,	limited	support	
from	HSCPs.
Community	 pharmacists	 could	 potentially	 develop	 an	 enhanced	
role	 in	supporting	medication	management	in	this	area.	The	support	
should	 be	 delivered	 in	 the	 person’s	 home,	 and	 the	 informal	 carer	
should	be	included	in	the	process.	It	should	include	practical	support	
to	help	them	organize	the	medication	and	develop	strategies	to	avoid	
medication	errors,	and	medication	review.	Barriers	to	an	expanded	role	
include	the	difficulty	accessing	pharmacy	services;	more	generally,	this	
is	an	issue,	which	should	receive	priority	in	terms	of	funding.	Informal	
carers	may	also	not	be	aware	of	this	potential	expanded	clinical	role.	
Community	pharmacists	would	need	to	develop	this	role	within	a	mul-
tidisciplinary	framework	with	access	to	full	clinical	records.
People	with	dementia	are	amongst	the	most	vulnerable	members	
of	society	with	needs	over	and	above	people	with	no	health	 issues.	
They	therefore	need	additional	support,	which	needs	to	be	recognized	
by	commissioners	of	 services.	Appropriate	care	pathways	should	be	
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established	to	provide	this	support;	community	pharmacists	can	be	a	
key	element	of	these	pathways.
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APPENDIX 
Demographic Details of Participants 
Interview number Interviewee(s) Gender Location Ethnicity
001 Person	with	dementia	and	Informal	carer Male	(M)	and	Female	(F) West	Midlands White	(both)
002 Informal	carer M South	West	England White
003 Person	with	dementia	&	Informal	carer M	&	F West	Midlands White	(both)
004 Informal	carer F North	East	England White
005 General	practitioner	(GP) F North	East	England White
006 Informal	carer F North	East	England White
007 Practice	nurse F North	East	England White
008 GP M London White
009 Practice	nurse F West	Midlands White
010 Paid	carer F West	Midlands White
011 Person	with	dementia M West	Midlands White
012 District nurse F West	Midlands White
013 District nurse F West	Midlands White
014 Person	with	dementia	and	Informal	carer M	&	F West	Midlands White	(both)
015 GP F North	West	England White
016 2	Informal	carers	(caring	for	the	same	
person)
M	&	F West	Midlands White	(both)
017 Paid	carer F South	East	England White
018 District/mental health nurse F West	Midlands White
019 GP F West	Midlands White
020 Paid	carer F South	East	England White
021 Community	pharmacist F Yorkshire White
022 Community	pharmacist M Yorkshire White
023 Community	pharmacist M London South	Asian
024 Community	pharmacist F South	West	England Not	known
025 Informal	carer M Yorkshire South	Asian
026 Informal	carer F Yorkshire South	Asian
027 Informal	carer F Yorkshire South	Asian
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Semi- structured Interview Schedule
1.	Interview	schedule	for	informal	carers/people	with	dementia:	A	qualitative	study	exploring	medication	management	in	people	with	dementia	
living	in	the	community	and	the	potential	role	of	the	community	pharmacist
This semi- structured interview will consist of open- ended questions, which are split into four sections. However, these questions will depend upon how 
much detail the participant wants to give. Due to the sensitive nature of this topic, participants will take some direction over this interview and some 
questions may be missed out or expanded upon. Minor amendments may be made as the interview progresses as issues may arise that the researcher had 
not considered.
INTRODUCTION
Before we begin this interview, could you confirm whether you are caring for someone with dementia?
Thank you for taking part in this interview, I really do appreciate the time you have given. Before we begin, I want to make it clear that if you 
wish to skip any question(s) during the interview, or if you want to stop the interview, all you have to do is say; you do not need to give any 
explanation for doing so.
Are	you	happy	for	me	to	begin?
Can	you	tell	me	a	bit	about	yourself?	For	example,	do	you	have	family	or	do	you	work?
Can	you	describe	what	a	typical	day	involves	for	you?
The next few questions are going to be in regard to medication.
(If	people	with	dementia)	Can	you	describe	to	me	any	practical	issues/concerns	(if	any)	you	find	with	taking	medication?
(If	carer)	Can	you	describe	to	me	any	practical	issues/concerns	(if	any)	you	find	with	assisting	somebody	with	their	medication?
Can	you	describe	to	me	any	strategies	you	use	to	organize	medication?
Prompt:	From	sorting	your	medication	to	taking	it	or	assisting	someone	to	take	it;	are	there	any	particular	methods/procedures	you	use	to	do	
this?
In this next section, I am going to ask a few questions with regard to taking (if interviewing the person with dementia) or assisting somebody 
(if the carer) in taking medication. I want to remind you that these questions are to help us better our understanding of how people feel about 
medication. Your replies will be treated so that no one will be able to identify that these are your answers.
(If	person	with	dementia)	Can	you	tell	me	about	a	time,	if	any,	you	have	decided	not	to	take	your	prescribed	medication?
(If	carer)	Can	you	tell	me	about	a	time,	if	any,	you	have	chosen	to	not	give	prescribed	medication	to	your	(whatever	the	relationship)?
Prompt:	Do	you	think	that	people	should	always	take	their	prescribed	medication?
What	would	you	describe	as	the	benefits	of	taking	medication?
Prompt:	In	your	opinion,	are	there	any	benefits	to	not	taking	medication?
Can	you	think	of	any	reasons	why	people	would	not	take	their	prescribed	medication?
The next section of questions will be about your experiences with medication:
In	your	opinion,	does	managing	your	medication	affect	your	daily	life?
Have	you	had	any	changes	to	medication	over	time?
If	yes,	can	you	tell	me	a	bit	about	that	and	how	it	made	you	feel?
If	no,	do	you	think	change	in	medication	over	time	would	have	an	effect	on	someone	in	your	situation?	If	yes,	in	what	way?
(If	carer)	Have	you	become	more	involved	in	assisting	in	the	organization	of	medication?
If	yes,	how	did	that	make	you	feel?
We are moving onto the last section of the interview now; this section is to do with your opinions and experiences with health-care 
professionals:
Can	you	tell	me	about	the	experiences	you	have	had	with	health-	care	professionals	(i.e.	GPs,	pharmacists,	social	care	workers)	over	the	past	
couple	of	years?
Prompt:	Have	you	had	any	notable	experiences	with	health-	care	professionals?
Can	 you	 describe	 to	 me	 your	 feelings	 about	 the	 level	 of	 support	 you	 have	 in	 regard	 to	 health-	care	 professionals	 helping	 you	 with	
medication?
How	do	you	think	health-	care	professionals	could	improve	support	to	people	with	dementia	and	their	carers	when	it	comes	to	helping	with	
medication	management?
Prompt:	Do	you	need	support	from	health-	care	professionals	 in	regard	to	medication	management?	If	yes,	what	kind	of	support	would	be	
helpful?
How	do	you	feel	about	the	future	in	terms	of	support	from	health-	care	professionals	in	helping	with	medication?
Prompt:	Do	you	think	health-	care	professionals	need	to	be	more	involved	in	supporting	people	with	dementia	and	their	carers	manage	their	
medication?
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Prompt:	What	health-	care	professional	do	you	think	would	be	most	helpful	in	offering	this	support?
Thank	you
Is	there	anything	that	you	would	like	to	add	or	any	questions	you	would	like	to	go	back	to?
End	of	Interview
2.	Interview	schedule	for	health	and	social	care	professionals:	A	qualitative	study	exploring	medication	management	in	people	with	dementia	
living	in	the	community	and	the	potential	role	of	the	community	pharmacist
This semi- structured interview will consist of open- ended questions, which are split into three sections. However, these questions will depend upon how 
much detail the participant wants to give. Participants will take some direction over this interview and some questions may be missed out or expanded 
upon. Minor amendments may be made as the interview progresses as issues may arise that the researcher had not considered.
INTRODUCTION
Before we begin this interview, could you please confirm what your job title is?
Thank you for taking part in this interview, I really do appreciate the time you have given. Before we begin, I would like to make it clear that 
if you wish to skip any question(s) during the interview, or if you want to stop the interview, all you have to do is say; you do not need to give 
any explanation for doing so.
Are	you	happy	for	me	to	begin?
Can	you	tell	me	what	your	current	role	is	in	regard	to	caring	for	people	with	dementia?
The next few questions are going to be about your experience of reviewing and assisting medication management for dementia patients and 
their carers that live at home (are not in residential care).
Can	you	tell	me	a	bit	about	your	experience	of	reviewing	or	helping	people	with	dementia	or	their	carers	manage	their	medication?
From	your	experience	and	your	own	opinion,	what	would	you	say	(if	any)	are	the	challenges	in	medication	management	for	dementia	patients	
and	their	carers?
Prompt:	Practical	challenges?	How	might	it	affect	their	lifestyle?
Do	you	feel	that	assisting/reviewing	medication	for	people	with	dementia	and	their	carers	is	a	part	of	your	role?
Prompt:	Can	you	describe	any	facilitators	or	barriers	that	help	or	hinder	you	from	assisting/reviewing	medication?
The next couple of questions are going to be about compliance/adherence to medication.
Can	you	tell	me	whether	you	have	ever	experienced	patients	who	have	dementia	not	adhere	to	prescribed	medication?
Prompt:	If	yes,	can	you	tell	me	a	bit	about	this	and	how	did	you	manage	this?
What	do	you	believe	could	be	the	potential	reasons	for	non-	adherence/non-	compliance	in	people	with	dementia/their	carers?
The last section of the interview focuses on your opinions about current practice.
Can	 you	 tell	me	 about	 your	 beliefs	 on	 the	 level	 of	 support	 available	 for	 people	with	 dementia	 and	 their	 carers	 in	 regard	 to	medication	
management?
How,	in	your	opinion,	do	you	think	the	service	could	improve?
Prompts:	In	order	to	make	any	improvements,	what	should	take	place?
In	your	opinion,	can	you	describe	to	me	the	role	that	community	pharmacy	plays	in	medication	management	in	people	with	dementia?
What	do	you	think	health-	care	professionals’	role	is	with	supporting	care	for	medication	management	in	people	with	dementia	and	their	carers	
who	dwell	in	the	community?
What	are	your	expectations	of	health-	care	professionals’	future	role	in	supporting	people	who	have	dementia	and	their	carers	with	regard	to	
medication	management?
Do	you	anticipate	much	change	happening	in	practice	regarding	this?
Thank	you.	Is	there	anything	that	you	would	like	to	add	or	any	questions	you	would	like	to	go	back	to?
End	of	Interview
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DOMAIN 2:  STUDY DESIGN
9. What methodological orientation was stated to underpin the 
study?
An exploratory, qualitative study was conducted employing semi-struc-
tured interviews. Data were analysed using framework analysis.
10. How were participants selected?
Informal carers were eligible if:
• They had provided or still provide some sort of assistance with medica-
tion management to a person who has been diagnosed with dementia 
and is living in the community;
• Do not receive any sort of payment (excluding carers’ allowance).
Health and social professionals were eligible if:
• they had been in contact with or had been providing assistance to peo-
ple with dementia
11. How were participants approached?
Participants were recruited from the Alzheimer’s society, Dementia UK, 
local surgeries and other professional networks, and local dementia sup-
port groups (including a support group for people with dementia in the 
black and minority ethnic [BME] community in Yorkshire). The institutions 
were contacted by LA and IM via telephone and email and asked about 
their willingness to collaborate in advertising the study. Also, they were 
provided with information and details of the research, what taking part in 
this study would involve and the criteria individuals had to meet to be able 
to participate.
Recruitment was also conducted through snowball effect as contacts 
were requested to suggest other PwD, informal carers and HSCPs who 
might be willing to take part in this study. After their approval to collabo-
rate in advertising this study, the contact details of IM and LA were pro-
vided and potential participants were free to contact IM and LA via email 
or phone to express their interest in participating. An email was then sent 
to all potential participants, who expressed an interest in the study, with 
an information sheet with details of the study and a consent form followed 
by a request of their availability in case they agreed in taking part.
12. How many participants were in the study?
The final sample comprised of 31 participants [eleven informal carers; 
four PwD, sixteen Health or Social Care Professionals (HSCPs). From the 
sixteen HSCPs, four were general practitioners, five were nurses (practice 
and district nurses), three were paid carers and four were community 
pharmacists].
13. How many people refused to participate or dropped out?
None.
14. Where was the data collected?
The interviews with carers and people with dementia were conducted in 
the person’s home. The interviews with health and social care professionals 
were conducted either face-to-face in their place of work or over the phone.
COREC GUIDELINES
DOMAIN 1:  RESEARCH TEAM AND REFLEXIVITY
1. Which author/s conducted the interview or the focus group?
The interviews were conducted by Lydia Aston, Tiago Moutela or Andrea Hilton. Ian Maidment provided supervision.
2. What were the researcher’s credentials?
IM and AH are both pharmacists experienced in dementia care. LA and TM are Health Psychologists in training with a Masters in Health Psychology 
(including a module in advanced qualitative methods).
3. What was their occupation at the time of the study?
LA and TM were RAs specifically employed on this project. IM was a Senior Lecturer in Clinical Pharmacy, Aston University. AH was a Senior Lecturer 
at Hull University and a practising Community Pharmacist.
4. Was the researcher male or female?
IM and TM are male; LA and AH female. (NB – IM, LA and AH would be classed as British White; TM as Portuguese).
5. What experience or training did the researcher have?
IM and AH are pharmacists experienced in dementia care. LA and TM have conducted numerous qualitative research projects as part of their Masters 
and working as RA’s at Aston University.
6. Was a relationship established prior to study commencement?
LA and TM did not know any of the participants prior to study commencement. AH personally knew one of the pharmacists (given the geographical 
location), full informed consent was gained. They introduced the topic before the interview started and formally introduced themselves; this included ex-
plaining their current role in the project.
7. What did the participants know about the researcher?
The participants knew that IM of Aston University was leading the research and it was funded by Pharmacy Research UK and that LA and TM were 
research assistants and that AH was an academic from Hull University.
8. What characteristics were reported about the interviewer/facilitator?
LA and TM reported that they were research assistants conducting interviews in this area with little clinical knowledge; AH reported that she was an 
academic from Hull University.
14  |     MAIDMENT ET Al.
15. Was anyone else present besides the participants and 
researchers?
No-one else was present except for interviews pp 025, 026 and 027 
when a translator/interpreter from the same community was present. The 
interpreter did not hold an official qualification however they were from 
the same background and spoke the same language as the participants. 
The interpreters had been involved in previous studies where they have 
translated and were identified by an academic from the same community. 
He was confident of the accuracy of the translation and the results were 
consistent with other findings.
16. What are the important characteristics of the sample?
Informal carers were eligible if: they had provided or still provide 
some sort of assistance with medication management to a person 
who has been diagnosed with dementia and is living in the commu-
nity and did not receive any sort of payment (excluding carers 
allowance).
Health and social professionals were eligible if they had been in contact 
with or had been providing assistance to people with dementia.
17. Were questions, prompts, guides provided by the authors? Was it 
pilot tested?
The interview schedule consisted of open-ended questions to avoid 
leading participants’ responses. Prompts were included in the schedule 
and were employed if required. LA and IM with support from AH devel-
oped the interview schedule. No pilot test took place.
18. Were repeat interviews carried out?
No interviews were repeated.
19. Did the research use audio or visual recording to collect the data?
A Dictaphone was used to record the interviews. Data were transcribed 
verbatim.
20. Were field notes made during and/or after the interview or focus 
group?
Additional notes were made during the interviews.
21. What was the duration of the interviews or focus group?
The length of each interview was not formally recorded. However, on 
discussion with LA, TM and AH, the interviews with HSCPs lasted on aver-
age approximately 20 to 30 minutes; the interviews with carers/PwD 60 
to 90 minutes.
22. Was data saturation discussed?
Data saturation was reached and discussed amongst all co-authors.
23. Were transcripts returned to participants for comment and/or 
correction?
Transcripts were not returned to the participants, but potential themes 
were discussed between all co-authors.
DOMAIN	3: 	ANALYSIS	AND	FINDINGS
24. How many data coders coded the data?
TM and IM independently reviewed the transcripts. Disagreements on 
the interpretation and analysis of the data were then discussed between 
TM and IM until consensus was achieved. A systematic cross-comparison 
analysis was undertaken by TM, and reviewed by IM to identify the simi-
larities and differences between the different participants and to develop 
a set of themes which represent the whole corpus of data. TM and IM then 
discussed and agreed the final structure of the matrix for the analysis.
25. Did authors provide a description of the coding tree?
No.
26. Were themes identified in advance or derived from the data?
Themes were derived from the data. Three key concepts were elicited 
from the data with subthemes within these three themes.
27. What software, if applicable, was used to manage the data?
NVIVO software was used to manage the data.
28. Did participants provide feedback on the findings?
Participants did not provide feedback.
29. Were participant quotations presented to illustrate the themes/
findings? Was each quotation identified?
Extracts presented in the results section were drawn directly from the 
transcripts, which are recordings of the interviews.
30. Was there consistency between the data presented and the 
findings?
Yes there was consistency between the data presented and the findings.
31. Were major themes clearly presented in the findings?
Three key concepts were elicited from the data with subthemes within 
these three themes, and all three themes were discussed in the results 
section.
32. Is there a description of diverse cases or discussion of minor 
themes?
Yes, diverse cases have been discussed and the differences between the 
interview data from the carers and HSCPs. When relevant, minor themes 
were discussed.
